Validation of the Sw71‐spheroid model with primary trophoblast cells
American Journal of Reproductive Immunology · 2023-12 · 90 (6)
DOI: 10.1111/aji.13800 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Reproductive Immunology, online erschienen am 23.11.2023. Verfasst von Marina Alexandrova und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biology and Immunology of Reproduction "Acad. Kiril Bratanov", Bulgarian Academy of Sciences, Sofia, Bulgaria. Hauptthemen laut MEDLINE: Trophoblasts, HLA-C Antigens. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: Bulgarian National Science Fund, VIHREN.
Abstract (Originalsprache)
Problem Human implantation is a limiting factor for the success of natural and IVF reproduction since about 60% of pregnancy losses occur in the peri‐implantation period. The in vitro modeling of human implantation challenges the researchers in accurate recreation of the complex in vivo differentiation and function of human blastocyst in the peri‐implantation period. In previous studies, we constructed Sw71‐spheroid models, which like human blastocyst undergo compactization, attaches to the endometrial epithelium, invade, and migrate. The aim of this study was to validate the trophoblast Sw71‐spheroid model with primary trophoblast cells, derived from healthy women in early pregnancy. Method of Study We performed a direct comparison of Sw71‐spheroid model with placenta‐derived primary trophoblasts regarding their hybrid phenotype and HLA status, as well as the ability to generate spheroids able to migrate and invade. From the primary trophoblast cells, isolated by mild enzymatic treatment and Percoll gradient separation, were generated long‐lived clones, which phenotype was assessed by FACS and immunocytochemistry.
Results
Our results showed that cultured primary trophoblasts have the EVT phenotype (Vim+/CK7+/HLA‐C+/HLA‐G+), like Sw71 cells. In both 3D culture settings, we obtained stable, round‐shaped, multilayered spheroids. Although constructed from the same number of cells, the primary trophoblast spheroids were smaller. The primary trophoblast spheroids migrate successfully, and in term of invasion are equally potent but less stable as compared to Sw71 spheroids.
Conclusions
The Sw71 cell line and cultured native trophoblast cells are interchangeable regarding their EVT phenotype (HLA‐C+/HLA‐G+/Vim+/CK7+). The blastocyst‐like spheroids sourced by both types of cells differentiate in the same time frame and function similarly. We strongly advise the use of Sw71 spheroids as blastocyst surrogate for observation on trophectoderm differentiation and function during early human implantation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biology and Immunology of Reproduction "Acad. Kiril Bratanov", Bulgarian Academy of Sciences, Sofia, Bulgaria.
- C.S. Mott Center for Human Growth and Development, Wayne State University, Detroit, Michigan, USA.
- Fetal medicine clinic, Medical University, University Obstetrics and Gynecology Hospital "Maichin Dom", Sofia, Bulgaria.
ORCID-Profile: Marina Alexandrova, Tanya Dimova
Förderung
- Bulgarian National Science Fund, VIHREN
Zitieren
APA
Alexandrova, M., Manchorova, D., You, Y., Terzieva, A., Dimitrova, V., Mor, G., & Dimova, T. (2023). Validation of the Sw71‐spheroid model with primary trophoblast cells. American Journal of Reproductive Immunology, 90(6). https://doi.org/10.1111/aji.13800
Vancouver
Alexandrova M, Manchorova D, You Y, Terzieva A, Dimitrova V, Mor G, et al. Validation of the Sw71‐spheroid model with primary trophoblast cells. American Journal of Reproductive Immunology. 2023;90(6). doi:10.1111/aji.13800
BibTeX
@article{Alexandrova2023,
author = {Alexandrova, Marina and Manchorova, Diana and You, Yuan and Terzieva, Antonia and Dimitrova, Violeta and Mor, Gil and Dimova, Tanya},
title = {Validation of the Sw71‐spheroid model with primary trophoblast cells},
journal = {American Journal of Reproductive Immunology},
year = {2023},
volume = {90},
number = {6},
doi = {10.1111/aji.13800}
}
EUVIMED